Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted.This app is only for health professionals. Subscribers to the journal Bulletin du Cancer are encouraged to use their login to the magazine. To obtain free login and password, please send an email to i-app@jle.com (subject: BDC), completed with your first name, name ans medical credentials.
免費玩BDC : Toxicities of targeted therapies and their management in renal cancer APP玩免費
免費玩BDC : Toxicities of targeted therapies and their management in renal cancer App
BDC : Toxicities of targeted therapies and their management in renal cancer APP LOGO
BDC : Toxicities of targeted therapies and their management in renal cancer APP QRCode
| 熱門國家 | 系統支援 | 版本 | 費用 | APP評分 | 上架日期 | 更新日期 |
|---|---|---|---|---|---|---|
| 未知 | iOS App Store | 1.0 App下載 | 免費 | 2012-02-24 | 2015-06-03 |
